Related references
Note: Only part of the references are listed.Validated HPLC-MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice
Naveena Madhyastha et al.
BIOMEDICAL CHROMATOGRAPHY (2021)
KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
Joshua K. Sabari et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Targeting KRAS in Cancer: Promising Therapeutic Strategies
Lisa Maria Mustachio et al.
CANCERS (2021)
P90.03 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
A. Spira et al.
Journal of Thoracic Oncology (2021)
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
M. Reck et al.
ANNALS OF ONCOLOGY (2021)
KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation
J. Tabernero et al.
ANNALS OF ONCOLOGY (2021)
Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry
Irene A. Retmana et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2021)
KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.
Tony S. K. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Jay B. Fell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Dongsung Kim et al.
CELL (2020)
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
M.L. Johnson et al.
EUROPEAN JOURNAL OF CANCER (2020)
KRasG12C inhibitors in clinical trials: a short historical perspective
Lisa Goebel et al.
RSC MEDICINAL CHEMISTRY (2020)
Optimized UPLC-MS/MS method for the quantitation of olanzapine in human plasma: application to a bioequivalence study
Ping Du et al.
BIOANALYSIS (2019)
A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study
Ping Du et al.
ANALYST (2019)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)